Health Canada Grants Quantum BioPharma a Product License for Its Innovative Product, Qlarity™, that Enhances Energy, and Promotes Metabolism, Mental Alertness and Cognitive Performance
Quantum BioPharma (NASDAQ: QNTM) has received a Product License (PN 80144141) from Health Canada for Qlarity™, its innovative natural health product. The license allows Quantum to market Qlarity in Canada with approved claims for enhancing energy production, metabolism, mental alertness, and cognitive performance.
The company has already licensed a similar product in the United States under the brand name unbuzzd™. This regulatory approval marks a significant milestone in Quantum's strategy to expand its portfolio of innovative biotech solutions for neurodegenerative and metabolic disorders.
Quantum BioPharma (NASDAQ: QNTM) ha ricevuto una Licenza di Prodotto (PN 80144141) dalla Health Canada per Qlarity™, il suo innovativo prodotto per la salute naturale. La licenza consente a Quantum di commercializzare Qlarity in Canada con affermazioni approvate per aumentare la produzione di energia, il metabolismo, la vigilanza mentale e la performance cognitiva.
L'azienda ha già ottenuto una licenza simile negli Stati Uniti con il marchio unbuzzd™. Questa approvazione regolamentare segna una pietra miliare significativa nella strategia di Quantum per espandere il proprio portafoglio di soluzioni biotecnologiche innovative per disturbi neurodegenerativi e metabolici.
Quantum BioPharma (NASDAQ: QNTM) ha recibido una Licencia de Producto (PN 80144141) de Health Canada para Qlarity™, su innovador producto de salud natural. La licencia permite a Quantum comercializar Qlarity en Canadá con afirmaciones aprobadas para aumentar la producción de energía, el metabolismo, la alerta mental y el rendimiento cognitivo.
La compañía ya ha licenciado un producto similar en Estados Unidos bajo la marca unbuzzd™. Esta aprobación regulatoria marca un hito importante en la estrategia de Quantum para ampliar su cartera de soluciones biotecnológicas innovadoras para trastornos neurodegenerativos y metabólicos.
Quantum BioPharma (NASDAQ: QNTM)가 Health Canada로부터 Qlarity™에 대한 제품 라이선스(PN 80144141)를 받았습니다. 이 라이선스로 Quantum는 캐나다에서 Qlarity를 허가된 주장으로 판매할 수 있으며 에너지 생산, 신진대사, 정신적 각성, 인지 성능의 향상을 강화하는 주장에 대해 허가를 받았습니다.
회사는 이미 미국에서 unbuzzd™라는 브랜드로 유사한 제품을 라이선스했습니다. 이 규제 승인은 신경퇴행성 및 대사 질환에 대한 혁신적 생명공학 솔루션 포트폴리오를 확장하려는 Quantum의 전략에 중요한 이정표가 됩니다.
Quantum BioPharma (NASDAQ: QNTM) a reçu une Licence de Produit (PN 80144141) de Santé Canada pour Qlarity™, son produit innovant de santé naturelle. La licence permet à Quantum de commercialiser Qlarity au Canada avec des allégations approuvées pour améliorer la production d'énergie, le métabolisme, la vigilance mentale et les performances cognitives.
L'entreprise a déjà obtenu une licence similaire aux États-Unis sous la marque unbuzzd™. Cette approbation réglementaire marque une étape importante dans la stratégie de Quantum pour étendre son portefeuille de solutions biotechnologiques innovantes pour les troubles neurodégénératifs et métaboliques.
Quantum BioPharma (NASDAQ: QNTM) hat von Health Canada eine Produktlizenz (PN 80144141) für Qlarity™, sein innovatives Naturheilprodukt, erhalten. Die Lizenz erlaubt Quantum, Qlarity in Kanada mit genehmigten Behauptungen zu vermarkten, die Energieproduktion, Stoffwechsel, mentale Wachheit und kognitive Leistung verbessern.
Das Unternehmen hat bereits ein ähnliches Produkt in den Vereinigten Staaten unter der Marke unbuzzd™ lizenziert. Diese behördliche Zulassung markiert einen bedeutenden Meilenstein in Quantum's Strategie zur Erweiterung seines Portfolios innovativer Biotech-Lösungen für neurodegenerative und metabolische Erkrankungen.
Quantum BioPharma (NASDAQ: QNTM) حصلت على ترخيص منتج (PN 80144141) من الحكومة الكندية للصحة لــ Qlarity™، منتجها الطبيعي الصحي المبتكر. يسمح الترخيص لـ Quantum بتسويق Qlarity في كندا مع ادعاءات معتمدة لـ تعزيز إنتاج الطاقة، الأيض، اليقظة العقلية، والأداء المعرفي.
الشركة قد منحت ترخيصاً سابقاً لمنتج مشابه في الولايات المتحدة تحت الاسم التجاري unbuzzd™. هذا الاعتماد التنظيمي يمثل علامة رئيسية في استراتيجية Quantum لتوسيع محفظتها من حلول التكنولوجيا الحيوية المبتكرة لاضطرابات الجهاز العصبي والتمثيلي.
Quantum BioPharma (NASDAQ: QNTM) 已从加拿大卫生部获得产品许可（PN 80144141），用于其创新的天然健康产品 Qlarity™。该许可允许 Quantum 在加拿大以经批准的声称销售 Qlarity，声称可以 提高能量产生、新陈代谢、精神警觉性和认知表现。
公司已在美国以 unbuzzd™ 品牌授权了类似产品。这项监管批准标志着 Quantum 扩展其创新生物科技解决方案组合以应对神经退行性和代谢性疾病的战略中的一个重要里程碑。
- Received Health Canada Product License approval for Qlarity™
- Expands market presence into Canada
- Product already licensed in US market under unbuzzd™ brand
- Multiple approved health claims for energy, metabolism, and cognitive performance
- None.
Insights
Health Canada's approval of Qlarity opens new revenue stream for Quantum BioPharma in the growing cognitive enhancement market.
Quantum BioPharma (NASDAQ: QNTM) has secured a significant regulatory milestone with Health Canada granting a Product License (PN 80144141) for Qlarity, its natural health product. This approval represents a tangible commercial opportunity in the Canadian market, complementing the company's existing U.S. presence where a similar product is sold under the unbuzzd™ brand.
The regulatory green light specifically permits marketing Qlarity with claims related to energy production, metabolism support, electrolyte balance, physical performance, mental alertness, and cognitive enhancement. This positions the product in the growing cognitive health and performance supplement market.
From a business perspective, this approval diversifies Quantum's revenue potential beyond its drug development pipeline focused on neurodegenerative and metabolic disorders. Natural health products typically have lower regulatory hurdles than pharmaceuticals, potentially offering faster paths to commercialization and revenue generation while the company advances its more complex drug candidates.
The Canadian natural health products market represents a strategic expansion opportunity, though the company has not provided projected revenue figures or market size estimates for Qlarity. The approval aligns with Quantum's stated mission of building a portfolio of innovative assets, adding a commercially-ready product to complement its developmental pipeline.
While this product license marks a positive development, investors should note that Qlarity represents just one component of Quantum's broader portfolio. The commercial success will depend on the company's marketing execution, consumer adoption, and the product's performance in an increasingly competitive wellness supplement landscape.
TORONTO, Sept. 18, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (Upstream: QNTM) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development, announces that Health Canada has granted a Product License (PN 80144141) for its natural health product, Qlarity. Quantum licensed a similar product, as a dietary supplement, for sale in the United States under the brand name unbuzzd™ (unbuzzd.com). This Product License from Health Canada permits Quantum to sell Qlarity in Canada.
Health Canada’s product license permits the following recommended uses of Qlarity, among others: helps in energy production and metabolism; helps to maintain/support normal electrolyte balance; helps (temporarily) to enhance (physical) energy and motor performance, reduce fatigue, promote endurance, promote mental alertness, and enhance cognitive performance.
“This is a milestone in Quantum BioPharma’s mission to bring innovative products to the market”, said Mr. Zeeshan Saeed, CEO of Quantum BioPharma. “We can now sell Qlarity to the Canadian market, leveraging its significant potential to improve consumer well-being.”
“I am delighted that the Natural Health Products Directorate at Health Canada has provided a Product License for Qlarity”, said Professor Lakshmi P. Kotra, a board director at Quantum BioPharma, a professor of medicinal chemistry at University of Toronto, and a senior scientist at the Krembil Research Institute, University Health Network. “I look forward to the launch of Qlarity in Canada, offering a solution to support energy, metabolism, mental alertness and cognitive performance”.
About Quantum BioPharma Ltd.
Quantum BioPharma (NASDAQ: QNTM) is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc. (“Lucid”), Quantum BioPharma is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. Quantum BioPharma invented unbuzzd™ and spun out its OTC version to a company, Celly Nutrition Corp. (“Celly Nutrition”), now Unbuzzd Wellness Inc., led by industry veterans. Quantum BioPharma retains ownership of
For more information visit www.quantumbiopharma.com.
Forward-Looking Information
This press release contains forward-looking statements under applicable securities laws, identified by terms like "may," "should," "anticipate," "expect," "potential," "believe," or "intend." These statements, based on assumptions and expected future events, involve risks and uncertainties that may cause actual results to differ materially from those expressed. For more details on risks, see Quantum BioPharma’s filings on SEDAR+ (www.sedarplus.ca) and EDGAR (www.sec.gov). Readers should not rely unduly on these statements, as there is no assurance that plans or expectations will occur. The Company assumes no obligation to update these statements except as required by law.
The reader is urged to refer to additional information relating to Quantum BioPharma, including its annual information form, which can be located on the SEDAR+ website at www.sedarplus.ca and on the EDGAR section of the United States Securities and Exchange Commission’s website at www.sec.gov for a more complete discussion of such risk factors and their potential effects.
Contacts:
Quantum BioPharma Ltd.
Zeeshan Saeed, Founder, CEO and Executive Co-Chairman of the Board
Email: Zsaeed@quantumbiopharma.com
Telephone: (833) 571-1811
Investor Relations
Investor Relations: IR@QuantumBioPharma.com
General Inquiries: info@QuantumBioPharma.com
FAQ
What is the Health Canada Product License number for Quantum BioPharma's Qlarity?
What are the approved health benefits of Qlarity according to Health Canada?
What is Quantum BioPharma's (QNTM) equivalent product to Qlarity in the United States?
Who is the CEO of Quantum BioPharma (QNTM)?
